Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma

Phase 2 Completed 39 enrolled Sun Yat-sen University Affiliated Cancer Hospital of Shantou University Medical College · collab First People's Hospital of Foshan · collab Fujian Cancer Hospital · collab Guangxi Medical University · collab Guangzhou Medical University · collab Hangzhou Cancer Hospital · collab Hubei Cancer Hospital · collab Hunan Provincial Cancer Hospital · collab Jiangxi Provincial Cancer Hospital · collab People's Hospital of Guangxi Zhuang Autonomous Region · collab Tongji Hospital · collab Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · collab Wuhan University · collab Zhejiang Cancer Hospital · collab

NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, uncontrolled, multicenter phase II clinical trial. The purpose of this study is to evaluate acute toxicity and efficacy of cisplatin and 5-Fu combined with nimotuzumab in patients with untreated metastatic nasopharyngeal carcinoma.

Timeline

Start: 2012-05
Primary completion: 2015-07
Completion: 2015-07

Publications

Zhao C, Miao J, Shen G, Li J, Shi M, Zhang N, Hu G, Chen X, Hu X, Wu S, Chen J, Shao X, Wang L, Han F, Mai H, Chua MLK, Xie C. Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial. Ann Oncol. 2019 Apr 1;30(4):637-643. doi: 10.1093/annonc/mdz020.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cisplatin	Other / unclassified	100 mg/m2	Intravenous
Subject	Nimotuzumab	Monoclonal antibody	200 mg	Intravenous
Subject	fluorouracil	Small molecule	1000 mg/m2	Intravenous

Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma

Summary

Timeline

Publications

Drugs

Indications